I also think that a lot of things are being put in place behind the scenes, and that is why things have been somewhat quiet.

Prior to the big Cytodyn Leadership to attend ESMO conference in Germany announcement, we had got news that Leronlimab reversed liver fibrosis and they were going to put together a trial to further demonstrate Leronlimab on fibrosis in other potential organs. That is a really huge deal, but once the ESMO train left the station it has been quiet.

I would think it has been quiet for a reason. I would venture a guess that things are being moved in place with a potential partner or partnerships.


I think everyone is busy working their tales off.


That’s my hope and I’m sticking to it.